Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results Read more about Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015 Read more about Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015
Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 Read more about Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration Read more about Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 Read more about Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12
Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option Read more about Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock Read more about Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
Agios Pharmaceuticals Announces Proposed Offering of Common Stock Read more about Agios Pharmaceuticals Announces Proposed Offering of Common Stock
Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors Read more about Agios Pharmaceuticals Appoints Kaye Foster-Cheek to its Board of Directors
Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency Read more about Agios Reports Positive Phase 1 Data in Healthy Volunteers for AG-348, a First-in-Class Investigational Medicine That Targets the Underlying Cause of Pyruvate Kinase (PK) Deficiency